Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ekso Bionics Holdings (EKSO) EBIT Margin (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed EBIT Margin for 13 consecutive years, with 143.6% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 9979.0% to 143.6% in Q4 2025 year-over-year; TTM through Dec 2025 was 104.12%, a 4576.0% decrease, with the full-year FY2025 number at 104.12%, down 4576.0% from a year prior.
  • EBIT Margin was 143.6% for Q4 2025 at Ekso Bionics Holdings, down from 33.17% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 33.17% in Q3 2025 to a low of 193.24% in Q2 2025.
  • A 5-year average of 102.7% and a median of 97.0% in 2022 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: skyrocketed 16134bps in 2021, then crashed -14607bps in 2025.
  • Ekso Bionics Holdings' EBIT Margin stood at 91.47% in 2021, then plummeted by -37bps to 124.92% in 2022, then skyrocketed by 43bps to 71.16% in 2023, then surged by 38bps to 43.81% in 2024, then crashed by -228bps to 143.6% in 2025.
  • Per Business Quant, the three most recent readings for EKSO's EBIT Margin are 143.6% (Q4 2025), 33.17% (Q3 2025), and 193.24% (Q2 2025).